Coronary reoperations in patients with a patent internal mammary artery graft provide good functional capacity and subjective improvement, justifying the procedure despite a 7% perioperative mortality.
Supports reoperation for functional gain in patent IMA patients; hypothesis-generating and requires prospective validation.
Objective: Analysis of short and long term results, clinical, functional and subjective status of patients, with a patent arterial graft, after coronary reoperation (RECABG). Methods: Perioperative and follow-up data of 71 patients, undergoing coronary reoperations (1987–8) were studied. A cross-sectional follow-up was conducted, functional evaluation by the Duke Activity Status Index (DASI). and patient's evaluation of his life situation were registered. Results: Perioperative mortality was 7%. Eleven patients died during follow-up. The 12-month and 60-month survival was 96% and 80%. Event-free survival was 86% and 51%. Family doctors declared that 55/66 (83%) had benefitted from the coronary reoperations. New York Heart Association decreased significantly from 3.4 ± 0.5 preoperative versus 1.5 ± 0.4 postoperative. The mean DASI was 38.06 ± 10.42. At the moment of the cross-sectional follow-up, 45/55 patients (82%) declared to have benefitted from the coronary reoperations. Conclusion: Improvement in New York Heart Association-class, good postoperative functional capacity, and patients positive evaluation, justify coronary reoperations in patients with a patent internal mammary artery graft.
No takes yet. Share an insight, caveat, or question.
Noyez et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: